Healthcare / BiotechnologyNasdaqCM
$3.61
+0.31 (+9.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-57.4M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$348M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-45.9%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-74.4M · FCF $-69.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Net Income | $-74.4M | $-74.4M | $-68.5M | $-51.8M | $-41.1M | $-20.9M | $-20.3M | $-30.4M | $-29.9M | $-20.3M | $-14.9M | $-11.4M | $-9.7M | $-6.7M | $-49287.00 | $-590215.00 |
| EBITDA | $-79.9M | $-79.9M | $-70.4M | $-56.0M | $-39.2M | $-22.9M | $-20.5M | $-25.9M | $-27.7M | — | — | — | $-5.2M | $-6.1M | — | — |
| EPS | -0.98 | -0.98 | -1.33 | -1.01 | -2.32 | -2.72 | — | — | — | — | — | — | -52.00 | -54.00 | — | -6.00 |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 | 0.54 | 0.00 | 0.00 | -0.86 | — | — | — | — | — | — | — |
| Current Ratio | 15.84 | 15.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-69.1M | $-69.1M | $-57.4M | $-44.6M | $-39.6M | — | $-24.2M | $-15.4M | $-14.1M | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | -45.9% | -45.9% | -56.6% | -44.6% | -27.5% | -80.1% | -276.1% | -1737.8% | 753.9% | -237.8% | -170.2% | -125.5% | -151.9% | 161.6% | 3.8% | 66.3% |
| Valuation | ||||||||||||||||
| P/B | 1.69 | 1.69 | 1.76 | 0.90 | 0.46 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| EPS Growth | 26.3% | 26.3% | -31.7% | 56.5% | — | — | — | — | — | — | — | — | 3.7% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.33 → -0.98
Residual
-12.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.